I期临床试验设计比较
Comparison of Phase I Clinical Trials
DOI: 10.12677/AAM.2023.1212502, PDF,   
作者: 李 萌, 张 洵：长沙理工大学，数学与统计学院，湖南 长沙
关键词: 3 + 3；持续再评估方法；贝叶斯最优区间设计；3 + 3； CRM； BOIN
摘要: I期临床可以分为基于规则、基于模型和基于模型辅助三种。选取上述三种设计具有代表性的设计，分别为3 + 3、CRM和BOIN，进行准确性和安全性评价。首先回顾三种设计的规则，区分三种规则之间的差异性；其次利用蒙特卡洛进行模拟，通过数值结果比较设计的准确性与安全性；最后对三种设计进行讨论。
Abstract: Phase I Clinical Trials can be divided into rule-based, model-based and model-assisted design three types. Select the above three representative designs, namely 3 + 3, CRM and BOIN, to evaluate the accuracy and safety. Firstly, review the three design rules and distinguish the differences among them. Secondly, Monte Carlo simulation is used to compare the accuracy and safety of the design through numerical results. Finally, three designs are discussed.
文章引用：李萌, 张洵. I期临床试验设计比较[J]. 应用数学进展, 2023, 12(12): 5120-5126. https://doi.org/10.12677/AAM.2023.1212502

参考文献

[1] Le Tourneau, C., Lee, J.J. and Siu, L.L. (2009) Dose Escalation Methods in Phase I Cancer Clinical Trials. Journal of the National Cancer Institute, 101, 708-720. [Google Scholar] [CrossRef] [PubMed]
[2] 李若冰, 何娟, 言方荣, 等. 抗肿瘤药物早期临床研究的新颖试验设计方法[J]. 中国新药杂志, 2021, 30(24): .
[3] Storer, B. and DeMets, D. (1987) Current Phase I/II Designs: Are They Adequate. Journal of Clinical Research and Drug Development, 1, 121-130.
[4] Liu, M., Wang, S.J. and Ji, Y. (2019) The i3+3 Design for Phase I Clinical Trials. Journal of Biophar-maceutical Statistics, 30, 1-11. [Google Scholar] [CrossRef] [PubMed]
[5] Simon, R., Rubinstein, L., Arbuck, S.G., Christian, M.C., Freidlin, B. and Collins, J. (1997) Accelerated Titration Designs for Phase I Clinical Tri-als in Oncology. Journal of the National Cancer Institute, 89, 1138-1147. [Google Scholar] [CrossRef] [PubMed]
[6] O’Quigley, J., Pepe, M. and Fisher, L. (1990) Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics, 46, 33-48. [Google Scholar] [CrossRef] [PubMed]
[7] Chevret, S. (1993) The Continual Reassessment Method in Cancer Phase I Clinical Trials: A Simulation Study. Statistics in medicine, 12, 1093-1108. [Google Scholar] [CrossRef] [PubMed]
[8] Saxena, A., Rubens, M., Ramamoorthy, V., et al. (2022) A Brief Overview of Adaptive Designs for Phase I Cancer Trials. Cancers, 14, Article No. 1566. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, S.S. and Yuan, Y. (2015) Bayesian Optimal Interval Designs for Phase I Clinical Trials. Journal of the Royal Statistical Society, 64, 507-523.
[10] Lee, S.M. and Cheung, Y.K. (2009) Model Calibration in the Continual Reassessment Method. Clinical Trials Journal of the Society for Clinical Trials, 6, 227-238.
[11] Zhou, H., Yuan, Y. and Nie, L. (2018) Accuracy, Safety, and Reliability of Novel Phase I Trial Designs Accuracy, Safety, and Reliability of Novel Phase I Designs. Clinical Cancer Research, 24, 4357-4364. [Google Scholar] [CrossRef] 

为你推荐